新型口服抗凝药与维生素 K 拮抗剂：在房颤患者中对健康相关生活质量的获益。
New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation.
机构信息
1. Grup de Recerca Cardiovascular, Hospital Universitari de Sant Joan, IISPV, Universitat Rovira i Virgili, Reus, Spain.
2. Hospital de la Sta. Creu i St. Pau, Barcelona, Spain.
出版信息
Int J Med Sci. 2014 May 1;11(7):680-4. doi: 10.7150/ijms.8916. eCollection 2014.
Abstract
New oral anticoagulants (NOAC) have demonstrated their efficacy as an alternative to vitamin K antagonists (VKA) in the prophylaxis of cardioembolic events in patients with atrial fibrillation (AF). However, evidence on the benefits of NOAC in health-related quality of life (HRQoL) is lacking.We evaluated changes in HRQoL related to oral anticoagulation therapy employing a specific questionnaire in a cohort of 416 patients with AF undergoing electrical cardioversion. In terms of HRQoL, we observed a progressive adaptation to treatment with VKA; satisfaction with NOAC remained constant. Older age, higher left ventricular ejection fraction and NOAC were associated with better HRQoL.
摘要
新型口服抗凝剂 (NOAC) 在预防房颤 (AF) 患者心源性栓塞事件方面已被证明优于维生素 K 拮抗剂 (VKA)。然而，关于 NOAC 在健康相关生活质量 (HRQoL) 方面的获益证据尚缺乏。我们采用特定问卷，对 416 例行电复律的 AF 患者进行评估，以了解与口服抗凝治疗相关的 HRQoL 变化。在 HRQoL 方面，我们观察到接受 VKA 治疗时逐渐适应，而对 NOAC 的满意度保持不变。高龄、左心室射血分数较高和使用 NOAC 与 HRQoL 更好相关。
相似文献
1
New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation.
Int J Med Sci. 2014 May 1;11(7):680-4. doi: 10.7150/ijms.8916. eCollection 2014.
2
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Europace. 2014 Aug;16(8):1137-44. doi: 10.1093/europace/euu007. Epub 2014 Feb 18.
3
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
Arch Cardiovasc Dis. 2018 Feb;111(2):74-84. doi: 10.1016/j.acvd.2017.04.007. Epub 2017 Sep 21.
4
Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.
Br J Clin Pharmacol. 2014 Oct;78(4):908-17. doi: 10.1111/bcp.12391.
5
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Heart Lung Circ. 2015 Jan;24(1):94-7. doi: 10.1016/j.hlc.2014.06.013. Epub 2014 Jul 3.
6
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Thromb Haemost. 2012 Oct;108(4):647-53. doi: 10.1160/TH12-01-0027. Epub 2012 Aug 23.
7
[Oral anticoagulation in atrial fibrillation: differential therapy with non vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA)].
MMW Fortschr Med. 2019 Oct;161(Suppl 6):15-23. doi: 10.1007/s15006-019-0920-y. Epub 2019 Oct 5.
8
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3.
9
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Int J Clin Pract. 2013 Jul;67(7):647-55. doi: 10.1111/ijcp.12177. Epub 2013 Apr 28.
10
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.
引用本文的文献
1
Predictors of dementia amongst newly diagnosed non-valvular atrial fibrillation patients.
Indian Heart J. 2022 Nov-Dec;74(6):505-509. doi: 10.1016/j.ihj.2022.11.009. Epub 2022 Nov 30.
2
The Risk of Bleeding Complications in Intra-Articular Injections and Arthrocentesis in Patients on Novel Oral Anticoagulants: A Systematic Review.
Cureus. 2021 Sep 6;13(9):e17755. doi: 10.7759/cureus.17755. eCollection 2021 Sep.
3
Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status.
Health Qual Life Outcomes. 2020 Dec 11;18(1):383. doi: 10.1186/s12955-020-01563-1.
4
Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study.
Health Qual Life Outcomes. 2020 Oct 20;18(1):347. doi: 10.1186/s12955-020-01600-z.
5
Watchman outcomes comparing post-implantation anticoagulation with warfarin versus direct oral anticoagulants.
J Interv Card Electrophysiol. 2021 Jun;61(1):137-144. doi: 10.1007/s10840-020-00790-2. Epub 2020 Jun 5.
6
Health-related quality of life in patients with atrial fibrillation: The role of symptoms, comorbidities, and the type of atrial fibrillation.
PLoS One. 2019 Dec 23;14(12):e0226730. doi: 10.1371/journal.pone.0226730. eCollection 2019.
7
Patient Satisfaction With Extended International Normalized Ratio Follow-up Intervals in a Veteran Population.
Ann Pharmacother. 2020 May;54(5):442-449. doi: 10.1177/1060028019889414. Epub 2019 Nov 21.
8
Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study.
Patient Prefer Adherence. 2019 Aug 14;13:1363-1373. doi: 10.2147/PPA.S204246. eCollection 2019.
9
Treatment Expectations, Convenience, and Satisfaction with Anticoagulant Treatment: Perceptions of Patients in South-East Queensland, Australia.
J Clin Med. 2019 Jun 17;8(6):863. doi: 10.3390/jcm8060863.
10
A systematic review of patient-reported outcomes associated with the use of direct-acting oral anticoagulants.
Br J Clin Pharmacol. 2019 Dec;85(12):2652-2667. doi: 10.1111/bcp.13985. Epub 2019 Jun 26.
本文引用的文献
1
A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.
Europace. 2014 Mar;16(3):308-19. doi: 10.1093/europace/eut373. Epub 2013 Dec 17.
2
Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Heart. 2014 Feb;100(4):324-35. doi: 10.1136/heartjnl-2013-304386. Epub 2013 Jul 22.
3
Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
Int J Cardiol. 2013 Oct 3;168(3):2540-7. doi: 10.1016/j.ijcard.2013.03.059. Epub 2013 May 8.
4
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
J Am Coll Cardiol. 2013 May 14;61(19):1998-2006. doi: 10.1016/j.jacc.2013.02.025. Epub 2013 Mar 14.
5
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
Clin Gastroenterol Hepatol. 2013 Mar;11(3):246-52.e1-5. doi: 10.1016/j.cgh.2012.10.021. Epub 2012 Oct 24.
6
Self-management of oral anticoagulation in elderly patients - effects on treatment-related quality of life.
Thromb Res. 2012 Sep;130(3):e60-6. doi: 10.1016/j.thromres.2012.06.012. Epub 2012 Jul 1.
7
Apixaban versus warfarin in patients with atrial fibrillation.
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
8
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
9
Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect.
J Am Coll Cardiol. 2010 May 25;55(21):2308-16. doi: 10.1016/j.jacc.2010.01.040.
10
Dabigatran versus warfarin in patients with atrial fibrillation.
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
Zotero 插件